Allergy Treatment Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)

The Report Covers Allergic Rhinitis Market Growth and it is Segmented by Type (Eye Allergy, Rhinitis, Asthma, Skin Allergy, Food Allergy, and Other Allergies), Treatment (Anti-allergy Drugs and Immunotherapy), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The Values are Provided in Terms of USD Million for above segment

Allergy Treatment Market Size

Single User License
Team License
Corporate License
Book before:
Allergy Treatment Market Summary
share button
Study Period 2024 - 2029
Market Size (2024) USD 21.05 Billion
Market Size (2029) USD 31.07 Billion
CAGR (2024 - 2029) 8.10 %
Fastest Growing Market Asia-Pacific
Largest Market North America

Major Players

Allergy Treatment Market Major Players

*Disclaimer: Major Players sorted in no particular order


Need a report that reflects how COVID-19 has impacted this market and its growth?

Single User License


Team License


Corporate License

Book before:

Allergy Treatment Market Analysis

The Allergy Treatment Market size is estimated at USD 21.05 billion in 2024, and is expected to reach USD 31.07 billion by 2029, growing at a CAGR of 8.10% during the forecast period (2024-2029).

During the COVID-19 pandemic, a large population was struggling with chronic respiratory issues, such as respiratory allergies, including allergic rhinitis and sinusitis. An article published in February 2021 in the Journal of Allergy and Clinical Immunology reported the pandemic had a significant impact on allergy & immunology (A&I) services, leading to multiple unplanned pragmatic amendments in service delivery. There is an urgent need for prospective audits and strategic planning to achieve equitable, safe, and standardized health care in the medium and long term. Thus, the pandemic substantially impacted market growth in its preliminary phase. However, per the analysis, the treatment market for the same grew significantly with the growing burden of allergic diseases in the post-pandemic phase. For instance, per the study published by the Journal of Family Medicine and Primary Care in 2022, 24 patients were admitted with complaints of facial edema, nasal crusting, and orbital swelling. All cases were diagnosed as invasive fungal sinusitis. Specifically, mucormycosis, supported by clinical and radiological findings and potassium hydroxide (KOH) mounting. Moreover, the latest treatment strategies for allergies and research on new treatment approaches are expected to drive the market in the coming years.

The increasing burden of various types of allergies, the growing investment by manufacturers in developing novel allergic treatments, and the rising importance of self-medication are the major factors propelling the market's growth. Allergic conditions are one of the most common health issues affecting children in the United States. For instance, in 2021, the Asthma and Allergy Foundation of America (AAFA) reported that each year in the United States, anaphylaxis (a severe allergic reaction) to food results in 90,000 emergency room visits, and more than 50 million people in the United States experience various types of allergies each year. Asthma and Allergy Foundation of America (AAFA) 2021 data also reported that approximately 24 million people in the United States were diagnosed with seasonal allergic rhinitis (hay fever). This equals around 8% (19.2 million) of adults and 7% (5.2 million) of children, and about 32 million people have food allergies. Thus, the growing prevalence of allergies is expected to increase demand for their treatment, thereby boosting the market's growth.

With the increase in allergic reactions, there are rising investments seen across the world for the development of novel treatments. For instance, in July 2022, Nestlé Health Science invested EUR 40 million (USD 41 million) to co-develop Enterome's preclinical IL-10 inducer and collaborate on discovering other food allergy candidates. Likewise, in February 2020, Aimmune Therapeutics also spent USD 10 million to in-license an experimental anti-allergenic biological drug from Xencor. Xencor granted Aimmune Therapeutics an exclusive worldwide license to develop and commercialize the investigational humanized monoclonal antibody AIMab7195 (originally XmAb7195). The drug was initially developed for the treatment of allergic asthma. It uses three distinct mechanisms of action to reduce blood serum IgE and suppress IgE-producing cells. All such factors are expected to propel the market during the forecast period.

However, the growing preference for low-cost biosimilars and lack of awareness regarding allergy immunotherapy can hamper the market's growth.

Allergy Treatment Market Trends

This section covers the major market trends shaping the Allergy Treatment Market according to our research experts:

Subcutaneous Immunotherapy (SCIT) Segment is Expected to Hold Significant Share in the Market Over the Forecast Period

Subcutaneous immunotherapy (SCIT) is the most effective and widely used allergy immunotherapy. So far, SCIT is the only treatment that alters the immune system and brings systemic relief. SCIT helps prevent the further development of new allergies and asthma.

A study published in the Journal of Allergy and Clinical Immunology in December 2021 demonstrated the clinical efficacy of all house dust mite immunotherapy modalities and suggests that SCIT may be more effective than SLIT drops or tablets in controlling symptoms of allergic rhinitis. Thus, the increased efficacy of SCIT for treating allergies is expected to boost the market's growth over the forecast period.

Additionally, per the study published in the International Archives of Allergy and Immunology in February 2021, subcutaneous allergen-specific immunotherapy (SCIT) is one of the main cornerstones in treating allergic rhinitis in pediatric patients. It demonstrated symptomatic relief and quality-of-life improvements but is not exempt from adverse reactions (ADRs). Thus, due to its safety established in pediatric patients, subcutaneous immunotherapy is expected to boost the segment over the forecast period.

The innovative launch of immunotherapy products and rising approval are major factors boosting the segments. In December 2021, the Omalizumab add-on offered efficacy benefits and improved allergen immunotherapy tolerability. Additionally, in July 2021, the United States FDA approved GSK's Nucala (mepolizumab), a monoclonal antibody that targets interleukin-5 (IL-5), as a treatment for patients with chronic rhinosinusitis with nasal polyps.

Thus, all the factors mentioned above, such as the safety and efficacy of SCIT and product launches, are expected to boost segment growth over the forecast period.

Allergy Treatment Market - Estimated Funding for Allergic Rhinitis (Hay Fever) (in USD millions), By Year, United States, 2020-2023

North America is Expected to Hold a Significant Share in the Market and Expected to do Same in the Forecast Period

North America is expected to hold a significant market share, with the United States accounting for the highest percentage. It is anticipated to maintain this trend throughout the forecast period.

The increase in allergy-related research activities and the increasing prevalence of allergies contribute to the regionregion's allergy treatment market growth published by the American College of Allergy, Asthma & Immunology, allergies are the sixth leading cause of chronic illness in the United States, with an annual cost of more than USD 18 billion, and more than 50 million Americans suffer from allergies each year. Food allergies among children and adults are increasing in the North American region. Thus, this surge in allergic diseases in the United States is expected to increase the demand for allergy treatment in the country. According to a study published in the December 2021 issue of the National Library of Medicine, rhinosinusitis affects an estimated 35 million people annually in the United States. It accounts for close to 16 million office visits per year. Thus, the rising prevalence of sinusitis is considered a positive indicator of the growth of the allergy treatment market.

Apart from the United States, the government of Canada is also focusing on providing Canadians with the information they require to make healthy and safe food choices. The CFIA (Canadian Food Inspection Agency) and Health Canada work with provincial, municipal, and territorial partners and industries to reach this goal.

Moreover, numerous drugs are under development in the United States, primarily to treat various types of allergies. Market players are focusing on the development and launch of new products. Anaphylaxis from occurring as a result of accidental peanut exposure. For instance, in April 2021, the FDA approved short ragweed pollen allergen extract to treat patients aged 5 to 65 years with short ragweed pollen-induced allergic rhinitis.

Thus, such factors as the rising burden of allergic diseases and government initiatives can lead to sustainable growth over the forecast period.

Allergy Treatment Market - Growth Rate by Region

Allergy Treatment Industry Overview

The allergy diagnostics market is fragmented, and competitive, and consists of several market players. Most allergy treatment products are manufactured by key global players. With more funds for research and better distribution systems, the market leaders established their positions in the market. Some of the market players are Johnson & Johnson, Sanofi, GlaxoSmithKline, F. Hoffmann-La Roche Ltd, and Leti Pharma.

Allergy Treatment Market Leaders

  1. Johnson & Johnson

  2. Sanofi SA

  3. GlaxoSmithKline PLC

  4. F. Hoffmann-La Roche Ltd. (Genentech Inc.)

  5. Leti Pharma

*Disclaimer: Major Players sorted in no particular order

Allergy Treatment Market Concentration
bookmark Need More Details on Market Players and Competitors?
Download PDF

Allergy Treatment Market News

  • In August 2022, Glenmark Pharmaceuticals' arm has launched the only-approved fixed-dose combination therapy for seasonal allergic rhinitis in the United States market.
  • In March 2022, Perrigo Company plc announced that it has received final approval from the US FDA for the over-the-counter use of Nasonex 24HR Allergy (mometasone furoate monohydrate 50mcg).

Allergy Treatment Market Report - Table of Contents


    1. 1.1 Study Assumptions and Market Definition

    2. 1.2 Scope of the Study




    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 The Increasing Importance for Self-medication

      2. 4.2.2 Rising Incidence of Food Allergies Worldwide

      3. 4.2.3 Rising Investments by Manufacturers on the Development of Novel Allergic Treatments

    3. 4.3 Market Restraints

      1. 4.3.1 Rise in Preference Toward the Use of Biosimilars

      2. 4.3.2 Low Awareness of Allergy Immunotherapy (AIT) Among Patients

    4. 4.4 Porter's Five Forces Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry

  5. 5. MARKET SEGMENTATION (Market Size by Value - USD million)

    1. 5.1 By Type

      1. 5.1.1 Eye Allergy

      2. 5.1.2 Rhinitis

      3. 5.1.3 Asthma

      4. 5.1.4 Skin Allergy

      5. 5.1.5 Food Allergies

      6. 5.1.6 Other Allergies

    2. 5.2 By Treatment

      1. 5.2.1 Anti-Allergy Drugs

        1. Antihistamines

        2. Corticosteroids

        3. Decongestants

        4. Other Drugs

      2. 5.2.2 Immunotherapy

        1. Sub-cutaneous Immunotherapy (SCIT)

        2. Sub-lingual Immunotherapy (SLIT)

    3. 5.3 Geography

      1. 5.3.1 North America

        1. United States

        2. Canada

        3. Mexico

      2. 5.3.2 Europe

        1. Germany

        2. United Kingdom

        3. France

        4. Italy

        5. Spain

        6. Rest of Europe

      3. 5.3.3 Asia-Pacific

        1. China

        2. Japan

        3. India

        4. Australia

        5. South Korea

        6. Rest of Asia-Pacific

      4. 5.3.4 Middle East and Africa

        1. GCC

        2. South Africa

        3. Rest of Middle East and Africa

      5. 5.3.5 South America

        1. Brazil

        2. Argentina

        3. Rest of South America


    1. 6.1 Company Profiles

      1. 6.1.1 ALK-Abello AS

      2. 6.1.2 AbbVie Inc.

      3. 6.1.3 Allergy Therapeutics

      4. 6.1.4 Bausch Health Companies Inc.

      5. 6.1.5 Alembic Pharmaceuticals Limited

      6. 6.1.6 F. Hoffmann-La Roche Ltd

      7. 6.1.7 Nicox SA

      8. 6.1.8 GlaxoSmithKline PLC

      9. 6.1.9 Johnson & Johnson

      10. 6.1.10 Leti Pharma

      11. 6.1.11 Novartis International AG

      12. 6.1.12 Sanofi SA

      13. 6.1.13 Teva Pharmaceutical Industries

    2. *List Not Exhaustive

**Subject to Availability
**Competitive Landscape Covers - Business Overview, Financials, Products and Strategies, and Recent Developments
bookmark You Can Purchase Parts Of This Report. Check Out Prices For Specific Sections
Get Price Break-up Now

Allergy Treatment Industry Segmentation

Allergy is a condition in which the immune system reacts abnormally to a foreign substance. Allergy treatment involves drugs and therapies that reduce the symptoms of allergies and help the immune system prepare for future encounters. The market is segmented by type (eye allergy, rhinitis, asthma, skin allergy, food allergy, and other allergies), treatment (anti-allergy drugs and immunotherapy), and geography (North America, Europe, Asia-Pacific, Middle-East and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 countries across major regions globally. The report offers the value (USD million) for the above segments.

By Type
Eye Allergy
Skin Allergy
Food Allergies
Other Allergies
By Treatment
Anti-Allergy Drugs
Other Drugs
Sub-cutaneous Immunotherapy (SCIT)
Sub-lingual Immunotherapy (SLIT)
North America
United States
United Kingdom
Rest of Europe
South Korea
Rest of Asia-Pacific
Middle East and Africa
South Africa
Rest of Middle East and Africa
South America
Rest of South America
customize-icon Need A Different Region Or Segment?
Customize Now

Allergy Treatment Market Research FAQs

The Allergy Treatment Market size is expected to reach USD 21.05 billion in 2024 and grow at a CAGR of 8.10% to reach USD 31.07 billion by 2029.

In 2024, the Allergy Treatment Market size is expected to reach USD 21.05 billion.

Johnson & Johnson, Sanofi SA, GlaxoSmithKline PLC, F. Hoffmann-La Roche Ltd. (Genentech Inc.) and Leti Pharma are the major companies operating in the Allergy Treatment Market.

Asia-Pacific is estimated to grow at the highest CAGR over the forecast period (2024-2029).

In 2024, the North America accounts for the largest market share in Allergy Treatment Market.

In 2023, the Allergy Treatment Market size was estimated at USD 19.47 billion. The report covers the Allergy Treatment Market historical market size for years: . The report also forecasts the Allergy Treatment Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.

Allergy Treatment Industry Report

Statistics for the 2024 Allergy Treatment market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Allergy Treatment analysis includes a market forecast outlook to 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!

Allergy Treatment Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)